Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Sign in

Welcome!Log into your account

your username

your password

Forgot your password?

Password recovery

Recover your password

your email

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Tag: GAVI

The € 7.4 billion for Covid-19 product and vaccine development needs...

Ellen 't Hoen - May 5, 2020

Recent Posts

We need a Global Vaccines Taskforce, not just a British or European one
The European Commission says Covid-19 vaccines should be global public goods, but do their agreements with pharma reflect this?
The elephant in the room at the WHO Executive Board
Wrapping up 2020 with some noteworthy medicines, law and policy events

Posts by Subject

Access to Medicines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Data exclusivity Delinkage DNDi dolutegravir European Commission European Union evergreening Fair Pricing Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands transparency TRIPS Council TRIPS flexibilities Truvada vaccines WHO WIPO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

This work is licensed under Creative Commons.